Cargando…

Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer

Molecular evaluation of EGFR mutation is indispensable in treating non-small cell lung cancer (NSCLC). We compared the results of EGFR analysis using tissue DNA (tDNA) and circulating tumor (ctDNA) to evaluate the feasibility of plasma as an effective material for detecting EGFR mutation and the rel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyunwoo, Han, Joungho, Choi, Yoon-La
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465683/ https://www.ncbi.nlm.nih.gov/pubmed/34574036 http://dx.doi.org/10.3390/diagnostics11091695

Ejemplares similares

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital
por: Choi, Yoon-La, et al.
Publicado: (2013)

The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors
por: Lee, Hyunwoo, et al.
Publicado: (2022)

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
por: Lee, Taebum, et al.
Publicado: (2016)

Selection Strategies and Practical Application of BRAF V600E-Mutated Non–Small Cell Lung Carcinoma
por: Hwang, Inwoo, et al.
Publicado: (2022)

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
por: Galvez‐Nino, Marco, et al.
Publicado: (2022)

Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America
por: Martin, Claudio, et al.
Publicado: (2022)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
por: Yu, Xiaoqing, et al.
Publicado: (2022)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world
por: Li, Haiyan, et al.
Publicado: (2020)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
por: Liu, Jun-Feng, et al.
Publicado: (2023)

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
por: Hu, Chunhong, et al.
Publicado: (2022)

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
por: Lee, Boram, et al.
Publicado: (2016)

Real‐world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non‐small cell lung cancer
por: Long, Chaolian, et al.
Publicado: (2023)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
por: Montella, Tatiane, et al.
Publicado: (2023)

Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States
por: Enewold, Lindsey, et al.
Publicado: (2016)

Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
por: Pereira, Isabel, et al.
Publicado: (2020)

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer
por: Shen, Chia-I, et al.
Publicado: (2022)

Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study
por: Molife, Cliff, et al.
Publicado: (2023)

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe
por: Hofman, P., et al.
Publicado: (2023)

Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
por: Kim, Jeong-Oh, et al.
Publicado: (2020)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
por: Park, Keunchil, et al.
Publicado: (2019)

Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study
por: Li, Hong-Shuai, et al.
Publicado: (2022)

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
por: Shi, Chao, et al.
Publicado: (2022)

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
por: Sun, Haiyan, et al.
Publicado: (2023)

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
por: Huang, Chun-Yao, et al.
Publicado: (2023)

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2023)

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
por: Dalurzo, Mercedes L, et al.
Publicado: (2021)

Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study
por: Cuppens, Kristof, et al.
Publicado: (2021)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
por: Phan, Thang Thanh, et al.
Publicado: (2019)

Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer
por: Kim, Insu, et al.
Publicado: (2023)

Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
por: Lee, Seung Eun, et al.
Publicado: (2019)

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
por: Ellison, Gillian, et al.
Publicado: (2013)

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
por: Tamura, Kazuo, et al.
Publicado: (2019)

Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
por: Cheng, Wen-Chien, et al.
Publicado: (2023)

Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
por: Li, Kelly, et al.
Publicado: (2023)

Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
por: Zhang, Mai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9uc3s2kmms1qddmh67gqa65pd6